Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02235064
Other study ID # CUH IRB#: 14-078
Secondary ID
Status Terminated
Phase N/A
First received August 8, 2014
Last updated February 27, 2018
Start date July 2014
Est. completion date July 2015

Study information

Verified date February 2018
Source The Cooper Health System
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this project is to assess the effectiveness of preventative antidepressants immediately following delivery on postpartum depression rates in women at high risk due to prior history of depression or postpartum depression.


Description:

Eligible women for our study would be identified antepartum from our three obstetrical groups delivering at Cooper University Hospital: Cooper Faculty Group, Women's Care Center, and CamCare. Potentially eligible women would be referred to the study coordinator or principal investigator to discuss the nature of the study. Those women who agreed to the trial would be further screened with a baseline structured psychiatric evaluation in the third trimester of the pregnancy to rule-out current depressive illness. If there was no evidence of depression at the antepartum evaluation, patients delivering a liveborn singleton fetus at 34 0/7 weeks or greater would be re-evaluated prior to discharge and, if scoring
Patients would be assigned to either sertraline 50 mg daily or identical appearing placebo for 12 weeks. Group allocation would be determined by restricted-randomization technique with variable block length, with the sequence generated by someone not associated with participant assignment. Assignment would be kept in sequentially numbered, opaque, sealed envelopes (SNOSE) in the pharmacy, which would dispense the medication (or placebo). Patients would be given a 30 day supply on the day of discharge, with refills provided by the study coordinator (through the pharmacy)for 12 weeks and a four-day supply of 25 mg Sertraline or placebo at the end of 12 weeks as a taper. Patients would also undergo follow-up blinded structured psychiatric evaluations at 4 weeks, 8 weeks, and 12 weeks to assess for adverse reaction to the assigned treatment agent, and for administration of questionnaires/evaluation to assess for development of depression. Any patient with recognized clinical depression would immediately be removed from further active participation in the study and referred to our Cooper Psychiatry department or outside psychiatrist for ongoing evaluation and treatment. Medication received (Sertraline or Placebo) would necessarily be revealed to Psych only for purposes of guiding appropriate further treatment.

All women randomized would be analyzed according to group assignment (intent-to-treat). Demographic information, including patient age, race/ethnicity, gravidity, parity, gestational age at delivery, infant birth weight, as well as infant weights from standard Pediatric visits (obtained verbally from the mother)would be recorded and compared using the Student t-test for normally distributed continuous data, Mann-Whitney U for non-normative continuous data, and the Chi Square test or Fisher Exact test for categorical data.

A sample size calculation was performed. Based on an anticipated rate of postpartum depression (PPD) of 30% in the placebo group, we would need 62 subjects in each group to detect a reduction in PPD to 10% in the sertraline group, with a power of .8 and a Type I error of .05. Based on the 2200 deliveries occurring annually at Cooper University Hospital, we anticipate that it would take 2-3 years to recruit 124 subjects into this study.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date July 2015
Est. primary completion date July 2015
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Past history of depression or postpartum depression

2. Singleton gestation

3. Delivery > 34 weeks gestation

4. No current clinical evidence of depression

5. Able to read and understand written English language

Exclusion Criteria:

1. Multiple gestation

2. Delivery prior to 34 weeks

3. Delivery outside of Cooper University Hospital

4. Major fetal anomaly or fetal demise

5. Current use of antidepressants

6. Evidence of active depression at antepartum evaluation

7. Edinburgh Postpartum Depression scale of >12 prior to discharge from the hospital

8. Maternal age < 18 years

9. Infant in Neonatal Intensive Care Unit (NICU) at time of patient discharge from hospital

10. Known or suspected allergy to Sertraline

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sertraline
Capsule containing crushed sertraline 50 mg tablets mixed with identically colored cellulose, with 4 day 25 mg taper
Placebo
Capsule containing cellulose powder of same color as experimental arm

Locations

Country Name City State
United States Cooper University Hospital Camden New Jersey

Sponsors (1)

Lead Sponsor Collaborator
The Cooper Health System

Country where clinical trial is conducted

United States, 

References & Publications (13)

ACOG Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008 Apr;111(4):1001-20. doi: 10.1097/AOG.0b013e31816fd910. Review. — View Citation

Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006 Feb 9;354(6):579-87. — View Citation

Gold LH. Postpartum disorders in primary care: diagnosis and treatment. Prim Care. 2002 Mar;29(1):27-41, vi. Review. — View Citation

Howard LM, Hoffbrand S, Henshaw C, Boath L, Bradley E. Antidepressant prevention of postnatal depression. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004363. Review. — View Citation

Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol. 2005 Dec;106(6):1289-96. — View Citation

Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005 May 18;293(19):2372-83. Review. — View Citation

Payne JL. Antidepressant use in the postpartum period: practical considerations. Am J Psychiatry. 2007 Sep;164(9):1329-32. Review. — View Citation

Pearlstein T, Howard M, Salisbury A, Zlotnick C. Postpartum depression. Am J Obstet Gynecol. 2009 Apr;200(4):357-64. doi: 10.1016/j.ajog.2008.11.033. Review. — View Citation

Safety of SSRIs in Pregnancy. Med Lett Drugs Ther. 2008 Nov 17;50(1299):89-91. Review. — View Citation

Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005 Feb 5-11;365(9458):482-7. — View Citation

Wisner KL, Perel JM, Peindl KS, Hanusa BH, Findling RL, Rapport D. Prevention of recurrent postpartum depression: a randomized clinical trial. J Clin Psychiatry. 2001 Feb;62(2):82-6. — View Citation

Wisner KL, Perel JM, Peindl KS, Hanusa BH, Piontek CM, Findling RL. Prevention of postpartum depression: a pilot randomized clinical trial. Am J Psychiatry. 2004 Jul;161(7):1290-2. — View Citation

Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, Ramin S, Chaudron L, Lockwood C. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol. 2009 Sep;114(3):703-13. doi: 10.1097/AOG.0b013e3181ba0632. Review. — View Citation

* Note: There are 13 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Development of Postpartum Depression up to 12 Weeks Following Discharge From Hospital Patients met with single psychiatrist (co-investigator), blinded to group assignment, who evaluated the patient using Edinburgh Postpartum Depression Screen, Hamilton Depression Rating Scale, Global Assessment of Functioning Scale, and clinical assessment
0 = No postpartum depression up to 12 weeks following discharge from hospital
1 = Postpartum depression up to 12 weeks following discharge from hospital
Discharge from hospital to 12 weeks postpartum
Secondary Number of Participants With Adverse Reaction to Treatment Agent up to 12 Weeks Following Discharge From Hospital The Antidepressant Side-Effect Checklist (ASEC) was employed to detect any adverse reaction to treatment regimens Discharge from hospital to 12 weeks postpartum
Secondary Reported Infant Weight at 4 Weeks Following Delivery 4 weeks postpartum
Secondary Number of Participants With Perceived Infant Sleeping Difficulty at 4 Weeks Postpartum 4 weeks postpartum
Secondary Number of Participants With Perceived Infant Feeding Difficulties 4 Weeks Postpartum 4 weeks postpartum
Secondary Reported Infant Weight at 8 Weeks Following Delivery 8 weeks postpartum
Secondary Reported Infant Weight at 12 Weeks Following Delivery 12 weeks postpartum
Secondary Number of Participants With Perceived Infant Sleeping Difficulty at 8 Weeks Postpartum 8 weeks postpartum
Secondary Number of Participants With Perceived Infant Sleeping Difficulty at 12 Weeks Postpartum 12 weeks postpartum
Secondary Number of Participants With Perceived Infant Feeding Difficulties 8 Weeks Postpartum 8 weeks postpartum
Secondary Number of Participants With Perceived Infant Feeding Difficulties 12 Weeks Postpartum 12 weeks postpartum
See also
  Status Clinical Trial Phase
Completed NCT04012580 - Examining the Effectiveness of Transdiagnostic, Internet-Delivered Cognitive Behaviour Therapy in New Mothers Experiencing Anxiety and Depression N/A
Recruiting NCT05813782 - The Effect of Baby Massage on Postpartum Depression and Maternal Attachment N/A
Recruiting NCT05907213 - Ketamine Tolerated Dose for Postpartum Depression and Pain After Cesarean Delivery Phase 1
Completed NCT00602732 - Interpersonal Treatment Program to Prevent Depression and Post-Traumatic Stress Disorder in Low-Income Pregnant Women With Partner Abuse Phase 1
Completed NCT00043602 - Clinician Managed Interpersonal Psychotherapy Phase 0
Completed NCT00053651 - Prevention of Postpartum Depression in Low-Income Women Phase 1
Completed NCT04169334 - Look - Your Baby is Talking to You. N/A
Completed NCT03573713 - Decreasing Stunting by Reducing Maternal Depression in Uganda: A Cluster Randomized Controlled Trial (CRCT) for Improved Nutrition Outcomes N/A
Completed NCT04043533 - The Effect of an Exercise Program in Reducing the Severity of Postpartum Depression in Women N/A
Completed NCT06070168 - Determining the Effect of Telephone Counseling Service Provided to Primiparous Mothers on Postpartum Depression N/A
Recruiting NCT05050266 - Enhancing Mental and Physical Health of Women Veterans N/A
Completed NCT02505984 - Preventing Postpartum Depression With Intranasal Oxytocin Phase 2
Recruiting NCT00251342 - Outcome of Postnatal Depression Screening Using Edinburgh Postnatal Depression Scale Phase 2/Phase 3
Completed NCT02526433 - The Impact of Creative Interventions on Symptoms of Postnatal Depression (Cohort Study) N/A
Completed NCT02526407 - The Impact of Creative Interventions on Symptoms of Postnatal Depression N/A
Completed NCT03574766 - Meditation for NICU Moms N/A
Completed NCT03646539 - RCT of Automated Conversational Agent vs. Treatment as Usual for the Management of Perinatal Mood N/A
Active, not recruiting NCT05110456 - To Evaluate the Effectiveness of a Virtual and Telephone Intervention for the Prevention of Postpartum Depression in Women at Risk N/A
Recruiting NCT04154423 - Engaging Mothers & Babies; Reimagining Antenatal Care for Everyone (EMBRACE) Study N/A
Not yet recruiting NCT04093791 - MAMA NO STRESS Project. The Effects of the "HAPPY MAMA" Intervention N/A